New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. MONTREAL / Nov 06, 2025 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems... Read More

SAN DIEGO / Oct 30, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic 1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic 1 basis, all... Read More

SAN DIEGO / Oct 27, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of... Read More

SAN DIEGO / Oct 02, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More

Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness on a global scale. Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom’s 2025 World Diabetes Day campaign. SAN DIEGO & BURNABY, British Columbia / Sep 10, 2025 /... Read More

SAN DIEGO / Aug 26, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025 at 2:15 pm (EDT) The Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 2:00 pm (EDT) Links to the webcast will be available on the Dexcom... Read More

SAN DIEGO / Jul 30, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic 1 basis. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic 1 basis, all on... Read More

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. BURNABY, British Columbia / Jul 30, 2025 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the... Read More

The new AI-powered Smart Food Logging feature supports greater personalized insights into how meals are impacting glucose levels Users can now take a photo of their food in their Stelo or Dexcom G7 app where AI will automatically identify the ingredients and populate the meal description SAN DIEGO / Jul 28, 2025 / Business Wire / DexCom, Inc. , the global leader in glucose biosensing, announced today it has released a new... Read More

Dexcom’s first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University’s Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier... Read More

SAN DIEGO / Jul 01, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More

New State of Type 2 Report in the United States reports that a majority of healthcare professionals (HCPs) surveyed believe continuous glucose monitoring will have the potential to be more impactful on the future of Type 2 diabetes care than advancements in diabetes medications. 1 Dexcom Warrior Lance Bass will share first-hand experience saying “Bye” to fingersticks* during panel at ADA. SAN DIEGO / Jun 18, 2025 / Business... Read More

SAN DIEGO / May 13, 2025 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer, which he has held since 2022. With more than 21 years of leadership experience at Dexcom, Mr. Leach helped steer the company’s biosensing platforms since the launch of its... Read More

SAN DIEGO / May 01, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic 1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic 1 basis, all on a... Read More

Dexcom’s first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. SAN DIEGO / Apr 22, 2025 / Business Wire / DexCom, Inc . (NASDAQ: DXCM), the global leader in glucose biosensing,... Read More

Dexcom G7 15 Day * is now cleared in the US for people age 18 years and above with diabetes. Now the longest lasting *,†,1 and most accurate 1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. For people between the ages 2 to 18, Dexcom G7 remains the most accurate 2 continuous glucose monitoring system. SAN DIEGO / Apr 10, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader... Read More

SAN DIEGO / Apr 03, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to review the company's first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be... Read More

BURNABY, British Columbia / Apr 01, 2025 / Business Wire / As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds this decision as a testament to the government’s commitment to improving diabetes care. The... Read More

SAN DIEGO / Mar 25, 2025 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom’s global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership... Read More

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system, 1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it the most accurate CGM sensor. 2 New Dexcom G7 automated insulin delivery and smart insulin pen integrations also announced at ATTD reinforce the company’s status as the most connected CGM brand in the world. 3 EDINBURGH, Scotland... Read More

SAN DIEGO / Mar 10, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President and Chief Operating Officer of Jazz... Read More

SAN DIEGO / Feb 27, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46 th Annual Raymond James Institutional Investors Conference on Tuesday, March 4 th . The live presentation is scheduled to begin at approximately 10:25 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at... Read More

SAN DIEGO / Jan 30, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold a conference call to review the company's fourth quarter and fiscal year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently... Read More

SAN DIEGO / Jan 13, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. International revenue is expected to be... Read More

Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform Dexcom GenAI-enabled technology will leverage Google Cloud’s Vertex AI platform and Gemini models and will initially enhance Stelo’s Weekly Insights feature by providing users with more personalized content based on glucose levels, activity and sleep Proprietary platform lays foundation for future GenAI... Read More

Alberta Government is now covering Dexcom G7, providing eligible residents living with either type 1 or type 2 diabetes with increased access to the life-changing technology BURNABY, British Columbia / Dec 17, 2024 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta... Read More

Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience Co-marketing efforts will help ŌURA and Dexcom reach millions of new users seeking better metabolic health Dexcom is investing $75 million in... Read More

Dexcom unveils new global data 1 which reveals nearly 70% of people with diabetes say they didn’t know where to begin their health journey when they were first diagnosed, and nearly half said diabetes has limited their ability to pursue a passion or interest Alongside Dexcom Warriors and Stelo Ambassadors, Dexcom invites people with diabetes to share their aspirations – whether small or large – helping them take the first... Read More

SAN DIEGO / Oct 24, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic 1 basis. U.S. revenue declined 2% and international revenue grew 12% on a reported basis and 16% on an organic 1 basis,... Read More

SAN DIEGO / Sep 26, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, October 24, 2024. Management will hold a conference call to review the company's third quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More

National Glucose Awareness Week will take place from Sept. 23-29, 2024, and will encourage people to learn about the importance of glucose and its significant impact on overall health, especially for people with diabetes. Retta, actress from Parks and Recreation, Good Girls and Hit Man, who is managing Type 2 diabetes, will... Read More

Kicking off its third season, Dexcom U welcomes four new athletes, including Shelomi Sanders, a rising star on the Alabama A&M University basketball team, to its diverse roster of 20 athletes with diabetes representing 12 sports across 18 colleges First-of-its-kind program continues to serve as a beacon of education and... Read More

Dexcom CGM is being worn by astronauts in space as part of the Polaris Dawn mission, which aims to better understand the effects of spaceflight on human health SAN DIEGO / Sep 10, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space... Read More

Dexcom EASD Symposium brings together expert panellists from across Europe to explore the transformational effects of Dexcom CGM on clinical practice. With the most extensive clinical data and evidence, Dexcom is the most experienced partner in Automatic Insulin Delivery (AID) 1 . Studies show the potential for Dexcom CGM to support therapy de-escalation and optimise diabetes management in Type 2 diabetes. 5,6,8 EDINBURGH,... Read More

SAN DIEGO / Aug 28, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, and Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4 th . The live presentation is scheduled to begin at approximately 11:00 AM EST and will be... Read More

Available for purchase today at Stelo.com for people in the U.S. 18 and older not using insulin Provides 24/7 powerful and personalized glucose insights directly to a smartphone, * revealing how food, exercise and sleep can affect glucose Tracking glucose just got easier, with no prescription and no fingersticks, ever... Read More

Québec becomes the latest province to offer public coverage for Dexcom G7, helping those living with type 1 diabetes access an innovative and effective management solution BURNABY, British Columbia / Aug 14, 2024 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM)... Read More

SAN DIEGO / Jul 25, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue grew 15% year-over-year to $1.004 billion on a reported basis and 16% year-over-year on an organic 1 basis. U.S. revenue grew 19% and international revenue grew 7% on a reported basis and 10% on an organic 1 basis, all on a... Read More

SAN DIEGO / Jun 27, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More

Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference. ADA conference presentations reiterate the advantages of Dexcom CGM use alongside incretin therapies such as GLP-1s. 1,2 New Dexcom G7 automated insulin delivery integrations * further solidify the company’s undisputed leadership in CGM connectivity. Recently released Dexcom G7... Read More

Diabetes management goes hands-free as Dexcom G7 now connects directly to Apple Watch * in the U.S., giving users confidence even when their iPhone isn’t with them † As the first and only CGM system that connects directly to Apple Watch, * Dexcom G7 gives users the freedom and convenience of real-time glucose readings on their... Read More

Nova Scotia becomes the latest province and territory to offer access to simple and easy-to-use diabetes management solutions, helping Canadians living with diabetes take control of their health BURNABY, British Columbia / Jun 03, 2024 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous... Read More

SAN DIEGO / May 29, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5 th . The live presentation is scheduled to begin at approximately 4:20 PM EST and will be concurrently webcast. Links to the webcast will be available... Read More

SAN DIEGO / Apr 25, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic 1 basis. U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on an... Read More

Report advances Dexcom’s corporate sustainability disclosures, including expanded greenhouse gas emissions data and greater transparency in pay-equity practices SAN DIEGO / Apr 03, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability... Read More

SAN DIEGO / Apr 02, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More

Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor worn on the back of the upper arm, Stelo will provide glucose insights directly to a user’s smartphone † Created by the makers of Dexcom G7, the most accurate, 1 easy-to-use 2 and clinically-proven CGM brand, 3-7 Stelo will... Read More

SAN DIEGO / Feb 27, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5 th . The live presentation is scheduled to begin at approximately 8:40 AM EST and will be concurrently webcast. Links to the webcast will be... Read More

SAN DIEGO / Feb 08, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic 1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported... Read More

SAN DIEGO / Jan 23, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently... Read More

The company also announced Stelo, its new glucose sensor for people with type 2 diabetes who do not use insulin, has been submitted to the U.S. Food and Drug Administration for review and is expected to launch in the U.S. in summer 2024 SAN DIEGO / Jan 08, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited... Read More

SAN DIEGO / Dec 19, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42 nd annual J.P. Morgan Healthcare Conference on January 8, 2024. The live presentation is scheduled to begin at approximately 12:45 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom... Read More

With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems 3,4 The clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when... Read More

SAN DIEGO / Nov 21, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper Sandler 35 th Annual Healthcare Conference on Wednesday, November 29 th . The live presentation is scheduled to begin at approximately 8:30 AM EST and will be concurrently webcast. Links to the webcast will be... Read More

Dexcom is helping the world #SeeDiabetes with a first-of-its-kind portrait gallery featuring the faces of people with diabetes from all walks of life and from all corners of the world, including celebrities Nick Jonas, Patti LaBelle and Jeremy Irvine. The #SeeDiabetes campaign and portrait gallery supports Dexcom’s ongoing... Read More

SAN DIEGO / Oct 26, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $975.0 million on a reported basis and 26% on an organic 1 basis. U.S. revenue growth of 24% and international revenue growth of 33% on a reported basis.... Read More

Dexcom G7 is available for people with all types of diabetes ages two years and older, giving more Canadians than ever access to a simple, accurate 1 and effective diabetes management solution BURNABY, British Columbia / Oct 05, 2023 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose... Read More

COMISAIR study is now the longest prospective real-world CGM study ever conducted, demonstrating significant and continued HbA1c reduction for patients using real-time CGM over seven years. 1 New data shows the Dexcom ONE CGM system delivers a clinically meaningful increase in time in range, reduction in HbA1c and improved glucose control for users with Type 2 diabetes. 2 Based on a recent study of 96 pregnant women... Read More

SAN DIEGO / Sep 29, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023. Management will hold a conference call to review the company's third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More

The partnership will pair cutting-edge technology from Dexcom with daily food tracking to provide a more comprehensive and personalized care experience for those living with diabetes BURNABY, British Columbia / Sep 21, 2023 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose... Read More

In its second season, the 2023 Dexcom U roster consists of 20 athletes with diabetes across 10 sports, 20 colleges, and includes 11 new team members Expanded program gives these collegiate athletes a platform to share their stories, serve as role models and inspire other people with diabetes SAN DIEGO / Sep 19, 2023 / Business... Read More

SAN DIEGO / Aug 30, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023 at 3:45pm (EDT). Sean Christensen, Vice President,... Read More

SAN DIEGO / Aug 28, 2023 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023. Ms. Driscoll is an accomplished leader with significant experience developing, guiding and executing organic and inorganic growth strategies for global organizations. She currently serves as... Read More

BURNABY, British Columbia / Aug 15, 2023 / Business Wire / Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that for the second consecutive year, it has been certified as a Great Place to Work ® in Canada for 2023-24. Awarded by Great Place to Work Institute ® , the global authority on workplace culture, this certification is based on direct feedback from... Read More

SAN DIEGO / Jul 27, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights: Revenue grew 25% versus the same quarter of the prior year to $871.3 million on a reported basis and 26% on an organic 1 basis. U.S. revenue growth of 21% and international revenue growth of 38% on a reported basis. International... Read More

SAN DIEGO / Jul 06, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call to review the company's second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More

Dexcom G7 is the most accurate CGM system 1 approved by Health Canada, building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hypoglycemia, and improve time in range 2,3,4 . Made with users in mind, Dexcom G7 combines simplicity and power, introducing a better way to manage diabetes... Read More

New Dexcom product with 15-day wear, a cash-pay option and a tailored software experience for people who don’t use insulin is expected to launch in the U.S. in 2024 Access and availability of Dexcom CGM is expanding globally, with Dexcom G7 now available in 14 countries and the recent launch of Dexcom ONE in Argentina marking the company’s first entrance into Latin America Private payers in the U.S. are following Medicare’s... Read More

SAN DIEGO / Jun 23, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced an update to its long-range financial targets at its 2023 Investor Day. Based on the company’s strong performance in the first two years of the target period, Dexcom is updating its year-end 2025 financial targets to the following levels: 2025 Revenue of approximately $4.6 - $5.1 billion (previously $4.0 - $4.5 billion) 2025 Non-GAAP Gross... Read More

SAN DIEGO / Jun 08, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23 rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations from Dexcom management highlighting the company’s market opportunities, business strategy, innovation efforts, and long-term financial outlook. Links to a live webcast of the event will... Read More

SAN DIEGO / Jun 01, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7 th . The live presentation is scheduled to begin at approximately 1:40 PM EST and will be concurrently webcast. Links to the webcast will be available on... Read More

SAN DIEGO / May 03, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate... Read More

SAN DIEGO / May 02, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the... Read More

SAN DIEGO / Apr 27, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights: Revenue grew 18% versus the same quarter of the prior year to $741.5 million on a reported basis and 19% on an organic 1 basis. U.S. revenue growth of 17% and international revenue growth of 21% on a reported basis. International... Read More

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and Inuit peoples for improved diabetes management BURNABY, British Columbia / Apr 27, 2023 / Business Wire / Dexcom, Inc. (NASDAQ:... Read More

Medicare patients using all types of insulin now have coverage for Dexcom G7 * – giving approximately 1.5 million more Americans access to the most accurate, 1 simple to use 1 CGM at the same cost as other CGM brands † Dexcom-backed MOBILE study was the primary piece of clinical evidence that led to the expansion of coverage 2... Read More

SAN DIEGO / Apr 06, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023. Management will hold a conference call to review the company's first quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will... Read More

Report advances Dexcom’s environmental, social, and governance (ESG) transparency by providing new disclosures, including company’s first greenhouse gas emissions inventory and enhanced human capital reporting SAN DIEGO / Apr 05, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report, which... Read More

BURNABY, British Columbia / Mar 21, 2023 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced that its Dexcom G6 CGM System will be available to people of all ages with type 1 and type 2 diabetes in Manitoba who meet eligibility criteria. Expanding coverage for rtCGM to include all eligible patients with type 1 or type 2 diabetes... Read More

SAN DIEGO / Mar 13, 2023 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article: “Dexcom does not have material exposure to the developments at Silicon Valley Bank, including with respect to the company’s cash deposits. Although the company has worked successfully with SVB for many years,... Read More

SAN DIEGO / Feb 23, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: Sean Christensen, Vice President, Finance and Investor Relations, will present on behalf of the company at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 2:45pm (EST). Jereme Sylvain,... Read More

SAN DIEGO / Feb 13, 2023 / Business Wire / Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System will be covered for Medicare beneficiaries. † Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, Dexcom G7 will be accessible to all... Read More

SAN DIEGO / Feb 09, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights: Revenue grew 17% versus the same quarter of the prior year to $815.2 million on a reported basis and 20% on an organic 1 basis. U.S. revenue growth of 17% and international revenue growth of 15% on a reported... Read More

SAN DIEGO / Feb 07, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today unveiled the company’s second Super Bowl commercial , which announces the US launch of its next-generation Dexcom G7 CGM System. The ad, which will run during the second quarter of Super Bowl LVII on Feb. 12, 2023, stars multi-platinum recording artist,... Read More

SAN DIEGO / Jan 24, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023. Management will hold a conference call to review the company's fourth quarter and full year 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently... Read More

Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program. Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits... Read More

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be at least $815 million, an increase of 17% over the fourth quarter of 2021 on a reported basis and 20% on an organic 1 basis. U.S. revenue is expected to be approximately $606 million, representing growth of 17% over the... Read More

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief commercial officer. In this role, Ms. Lawver will oversee the global commercial organization with responsibility for global sales, marketing and customer experience. Ms. Lawver comes to Dexcom with extensive healthcare and global... Read More

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41 st annual J.P. Morgan Healthcare Conference on January 9, 2023. The live presentation is scheduled to begin at approximately 2:15 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at... Read More